DOCSLIB.ORG

Functions of the Adapter Protein Cas: Signal Convergence and the Determination of Cellular Responses

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Functions of the Adapter Protein Cas: Signal Convergence and the Determination of Cellular Responses Oncogene (2001) 20, 6448 ± 6458 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc Functions of the adapter protein Cas: signal convergence and the determination of cellular responses Amy H Bouton*,1, Rebecca B Riggins1 and Pamela J Bruce-Staskal1 1Department of Microbiology, University of Virginia School of Medicine, Box 800734, Charlottesville, Virginia VA 22908, USA Since Cas was ®rst identi®ed as a highly phosphorylated Cas and its family members 130 kilodalton protein that associated with the v-Src and v-Crk-oncoproteins, considerable eort has been made to Cas was ®rst identi®ed as a pTyr-containing 130 kDa determine its function. Its predicted role as a scaolding protein in cells transformed by the oncogenes v-src and molecule based on its domain structure has been largely v-crk (Matsuda et al., 1990; Reynolds et al., 1989). con®rmed. Through its ability to undergo rapid changes Transformation by both of these oncogenes requires in phosphorylation, subcellular localization and associa- protein tyrosine kinase (PTK) activity; in the case of v- tion with heterologous proteins, Cas may spatially and Src, PTK activity is provided by its own intrinsic temporally regulate the function of its binding partners. catalytic activity (Jove and Hanafusa, 1987), whereas Numerous proteins have been identi®ed that bind to Cas expression of v-Crk induces the PTK activity of a in vitro and/or in vivo, but in only a few cases is there an heterologous kinase (Mayer et al., 1988; Mayer and understanding of how Cas may function in these protein Hanafusa, 1990a). The 130 kDa protein (p130), which complexes. To date, Cas-Crk and Cas-Src complexes was later identi®ed as Cas, was found to associate with have been most frequently implicated in Cas function, activated variants of cellular Src (c-Src, Src) and v-Crk particularly in regards to processes involving regulation (Matsuda et al., 1990, 1991; Mayer and Hanafusa, of the actin cytoskeleton and proliferation. These and 1990a; Reynolds et al., 1989). Mutations in v-Src and other Cas protein complexes contribute to the critical v-Crk that abrogated binding of this 130 kDa protein role of Cas in cell adhesion, migration, proliferation and also abolished the transforming activity of these survival of normal cycling cells. However, under oncoproteins, suggesting that p130 played a critical conditions in which these processes are deregulated, role in the transformation process (Kanner et al., 1991; Cas appears to play a role in oncogenic transformation Mayer and Hanafusa, 1990b). and perhaps metastasis. Therefore, in its capacity as an A cDNA clone encoding Cas was isolated in 1994 adapter protein, Cas serves as a point of convergence for (Sakai et al., 1994a,b) and its predicted domain many distinct signaling inputs, ultimately contributing to structure suggested that it functioned as an adapter the generation of speci®c cellular responses. Oncogene or scaolding molecule (Figure 1). Cas contains an (2001) 20, 6448 ± 6458. amino-terminal src-homology 3 (SH3) domain, followed by a short proline-rich segment, a large Keywords: Cas; Src; Crk; Rac1; migration; adapter `substrate-binding' domain containing ®fteen repeats of a four amino acid sequence (tyrosine-any two amino acids-proline; YXXP), a serine-rich region and Cas (p130Cas; Crk-associated substrate) was ®rst a carboxy-terminal domain. The YXXP motif found recognized over 10 years ago as a 130 kilodalton in the substrate-binding domain can serve as a PTK (kDa) phosphotyrosine (pTyr)-containing protein that substrate (Songyang, 2001; Songyang et al., 1994; associated with two oncoproteins, pp60v-src (v-Src) and Songyang and Cantley, 1998), leading to phosphor- p47gag-crk (v-Crk) (Matsuda et al., 1990; Reynolds et al., ylation of one or more tyrosine residues. Once 1989). Following cloning of the Rat cDNA in 1994 phosphorylated, these tyrosine residues can then (Sakai et al., 1994a,b), tremendous eorts have been serve as ligands for src-homology 2 (SH2) or pTyr placed on determining the function of Cas in both binding (PTB) domains contained in many dierent oncogenic and normal cellular processes. This review cellular proteins. Within the carboxy-terminal half of will begin with a short perspective on Cas and its Cas, there are several additional protein interaction family members. It will then discuss some of the known sites (Burnham et al., 1996). The predicted function functions of Cas and explore possible mechanisms of Cas as an adapter protein has been borne out through which Cas may perform these functions. through the identi®cation of numerous binding Finally, it will investigate potential roles for Cas in partners (Figure 1). While several of these interac- the development and/or progression of oncogenesis. tions have been detected in vivo following activation of speci®c signaling pathways, the regulation and function of many Cas protein complexes remain *Correspondence: AH Bouton; E-mail: [email protected] unresolved. Functions of the adapter protein Cas AH Bouton et al 6449 Figure 1 Cas structure and its binding partners. A graphic depiction of the domain structure of Cas is shown, including the SH3 domain (SH3), proline-rich region (PRO), substrate-binding YXXP domain (YXXP15), serine-rich region (SER) and carboxy- terminus (C-terminus). The bipartite Src binding sequence is indicated by single letter amino acid codes; the Src SH3 domain binds to the sequence RPLPSPP beginning at residue 639 and the Src SH2 domain binds to the sequence motif pYDYV beginning at residue 668 (Nakamoto et al., 1996). Proteins that have been shown to bind to the domains of Cas, either in vitro or in vivo, are presented below. A partial list of references that address binding of these proteins to Cas includes: Fak (Burnham et al., 1996; Harte et al., 1996; Polte and Hanks, 1995), Pyk2 (Astier et al., 1997b; Lakkakorpi et al., 1999), FRNK (Harte et al., 1996), PTP1B (Liu et al., 1996), PTP-PEST (Garton et al., 1996), C3G (Kirsch et al., 1998), PR-39 (Chan and Gallo, 1998), CMS (Kirsch et al., 1999; Nakamoto et al., 2000), Crk (Burnham et al., 1996; Sakai et al., 1994a), Nck (Schlaepfer et al., 1997), PI3K (Li et al., 2000), SHIP2 (Prasad et al., 2001), 14-3-3 (Garcia-Guzman et al., 1999), Src family kinases (Burnham et al., 1996; Nakamoto et al., 1996; Sakai et al., 1994a), NSP family members (Gotoh et al., 2000; Lu et al., 1999; Sakakibara and Hattori, 2000), Grb2 (Wang et al., 2000), Nephrocystin (Donaldson et al., 2000), PI3K (Li et al., 2000), ID2 (Law et al., 1999), CIZ (Nakamoto et al., 2000) There are two other family members that share suggest that they have potentially distinct functions. considerable structure and sequence homology with First, the expression patterns of these three proteins Cas. Human enhancer of filamentation HEF1/CasL dier signi®cantly. Whereas Cas mRNA and protein (HEF1) was identi®ed in 1996 as a `lymphocyte-type' are expressed in most adult tissues, HEF1 mRNA Cas family member that promoted pseudohyphal levels are signi®cantly reduced in brain and liver, and growth in the budding yeast Saccharomyces cerevisiae HEF1 protein levels appear to be greatest in (Law et al., 1996; Minegishi et al., 1996). Embryonal lymphocytes, lung and breast epithelium (Law et al., Fyn-associated substrate (Efs)/Src-interacting protein 1996, 1998; Minegishi et al., 1996; Sakai et al., 1994a). (Sin) was identi®ed about the same time as a Fyn/Src- Expression of Efs/Sin is considerably more restricted, associated protein (Alexandropoulos and Baltimore, with the highest levels of mRNA being present in 1996; Ishino et al., 1995). Both HEF1 and Efs/Sin embryonic tissues (Ishino et al., 1995). Second, there is share a similar domain structure with Cas, with the some indication that the three family members may greatest sequence similarity present in the SH3 undergo distinct post-translational modi®cations and domains and the carboxy-terminal 200 amino acids exhibit unique localization patterns within the cell. All (Figure 2). One of the most notable dierences three molecules are predominantly cytoplasmic, but a between the functional sequence motifs of these fraction of Cas and HEF1 is found in focal adhesions proteins is found in the Src binding sequences. The of adherent cells (Harte et al., 1996, 2000; Law et al., bipartite binding site present in Cas and Efs/Sin 1996, 2000; Nakamoto et al., 1997; Petch et al., 1995; includes a proline-rich region that binds to the Src Polte and Hanks, 1995). HEF1 undergoes a speci®c SH3 domain and a pTyr-containing sequence that cleavage event during mitosis, culminating in the binds to the Src SH2 domain (Alexandropoulos and appearance of a biologically active amino-terminal Baltimore, 1996; Burnham et al., 1999, 2000; fragment that localizes to the mitotic spindle (Law Nakamoto et al., 1996). The SH3-binding sequence et al., 1998). Cas also undergoes post-translational is absent from HEF1 (Figure 2). It is unclear how this modi®cations during mitosis, characterized by a change aects Src binding to HEF1, but Cas dramatic loss of tyrosine phosphorylation and a molecules with proline-to-alanine substitutions in these concomitant increase in serine phosphorylation sequences exhibit reduced binding to Src (Burnham et (Yamakita et al., 1999). Third, there is evidence to al., 1999, 2000; Nakamoto et al., 1996). suggest that HEF1 and Efs/Sin are unable to While the three Cas family members share a genetically and/or functionally substitute for Cas common domain structure, several lines of evidence during embryonic development. Mouse embryos con- Oncogene Functions of the adapter protein Cas AH Bouton et al 6450 Figure 2 Cas family members. The domain structures of Cas, HEF1 and Efs/Sin are shown. Domains include the SH3 domain (SH3), proline-rich region (PRO), substrate-binding YXXP domain (YXXP), serine-rich region (SER) and carboxy-terminus (C- terminus) The bipartite Src binding sequences present on Cas and Efs/Sin are indicated by single letter amino acid codes.
Load more

Recommended publications
  • Sample Lab Report
    3030 Venture Lane, Suite 108 ● Melbourne, Florida 32934 ● Phone 321-253-5197 ● Fax 321-253-5199 PATIENT: DOE, JAMES ACCESSION NO: CLINICIAN/ PATIENT ID: REQUESTING DATE OF BIRTH: 1/5/1986 DOCTOR: GENDER: MALE DATE COLLECTED: 5/26/2015 DATE OF REPORT: 6/15/2015 RESULTS PRIMARY TUMOR TYPE RIGHT TESTICLE BIOLOGICALLY IMPORTANT ONCOGENES DETECTED GENE IMPLICATION TP53 TP53 mutations may be an important driver of tumorigenesis and / or a reason for treatment resistance in a some patients. PTEN Responsible for uncontrolled growth. MDM2 Causes p53 inactivation. Associated with cancer growth and progression. TGFB1 TGFB appears to promote tumor progession by stimulating invasion and metastasis. TUBB2A Microtubules are the key components of the cytoskeleton of eukaryotic cells and have an important role in various cellular functions such as intracellular migration and transport, cell shape maintenance, polarity, cell signaling and mitosis. c-JUN Proto-oncogene PHB2 Prohibitins play a crucial role in adhesion processes in the cell and thereby sustaining cancer cell propagation and survival. Clinical Impression: Low Aggressive Potential Additional Genes Detected: ABCG2, ARHGAP5, ATF4, BIRC5, BNIP3, CAPNS1, CARD17, CCNB1, CD24, CDC20, CDK18, CKS2, DCN, DEPDC1, FTL, FZD5, FZD9, GAPDH, GNB2, GPR126, H2AFZ, HDAC1, HMGN2, ID1, IFITM1, JUNB, KPNA2, KRT18, LDHA, LTF, MAD2L1, MAP2K1, MAP2K2, MAP2K4, MAPRE1, MAS1, NME1, NME3, NPM1, PA2G4, PABPC1, PFDN4, PGAM1, PGK1, PHB, PIK3CB, PKM, PPIA, PPIH, PRKX, PRNP, PTMA, RAC1, RAC2, RALBP1, RAP1A, RBBP4, RHOB, RHOC,
    [Show full text]
  • Paxillin Binding to the Cytoplasmic Domain of CD103 Promotes Cell Adhesion and Effector
    Author Manuscript Published OnlineFirst on October 11, 2017; DOI: 10.1158/0008-5472.CAN-17-1487 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Paxillin binding to the cytoplasmic domain of CD103 promotes cell adhesion and effector functions for CD8+ resident memory T cells in tumors Ludiane Gauthier1, Stéphanie Corgnac1, Marie Boutet1, Gwendoline Gros1, Pierre Validire2, Georges Bismuth3 and Fathia Mami-Chouaib1 1 INSERM UMR 1186, Integrative Tumor Immunology and Genetic Oncology, Gustave Roussy, EPHE, Fac. de médecine - Univ. Paris-Sud, Université Paris-Saclay, 94805, Villejuif, France 2 Institut Mutualiste Montsouris, Service d’Anatomie pathologique, 75014 Paris, France. 3 INSERM U1016, CNRS UMR8104, Université Paris Descartes, Institut Cochin, 75014 Paris. S Corgnac, M Boutet and G Gros contributed equally to this work. M Boutet current address: Department of Microbiology and Immunology Albert Einstein College of Medecine, NY 10461 USA. Corresponding author: Fathia Mami-Chouaib, INSERM UMR 1186, Gustave Roussy. 39, rue Camille Desmoulins, F-94805 Villejuif. Phone: +33 1 42 11 49 65, Fax: +33 1 42 11 52 88, e-mail: [email protected] and [email protected] Running title: CD103 signaling in human TRM cells Key words: TRM cells, CD103 integrin, T-cell function and signaling, paxillin. Abbreviations: IS: immune synapse; LFA: leukocyte function-associated antigen; FI: fluorescence intensity; mAb: monoclonal antibody; phospho: phosphorylated; Pyk2: proline- rich tyrosine kinase-2; NSCLC: non-small-cell lung carcinoma; r: recombinant; sh-pxn: shorthairpin RNA-paxillin; TCR: T-cell receptor; TIL: tumor-infiltrating lymphocyte; TRM: tissue-resident memory T.
    [Show full text]
  • Paxillin: a Focal Adhesion-Associated Adaptor Protein
    Oncogene (2001) 20, 6459 ± 6472 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc Paxillin: a focal adhesion-associated adaptor protein Michael D Schaller*,1 1Department of Cell and Developmental Biology, Lineberger Comprehensive Cancer Center and Comprehensive Center for In¯ammatory Disorders, University of North Carolina, Chapel Hill, North Carolina, NC 27599, USA Paxillin is a focal adhesion-associated, phosphotyrosine- The molecular cloning of paxillin revealed a number containing protein that may play a role in several of motifs that are now known to function in mediating signaling pathways. Paxillin contains a number of motifs protein ± protein interactions (see Figure 1) (Turner that mediate protein ± protein interactions, including LD and Miller, 1994; Salgia et al., 1995a). The N-terminal motifs, LIM domains, an SH3 domain-binding site and half of paxillin contains a proline-rich region that SH2 domain-binding sites. These motifs serve as docking could serve as an SH3 domain-binding site. Several sites for cytoskeletal proteins, tyrosine kinases, serine/ tyrosine residues conforming to SH2 domain binding threonine kinases, GTPase activating proteins and other sites were also noted. In addition, the N-terminal adaptor proteins that recruit additional enzymes into domain of paxillin contains ®ve copies of a peptide complex with paxillin. Thus paxillin itself serves as a sequence, called the LD motif, which are now known docking protein to recruit signaling molecules to a to function as binding sites for other proteins (see speci®c cellular compartment, the focal adhesions, and/ Table 1) (Brown et al., 1998a). The C-terminal half of or to recruit speci®c combinations of signaling molecules paxillin is comprised of four LIM domains, which are into a complex to coordinate downstream signaling.
    [Show full text]
  • Conditional Ablation of P130cas/BCAR1 Adaptor Protein
    Camacho Leal et al. Cell Communication and Signaling (2018) 16:73 https://doi.org/10.1186/s12964-018-0289-z RESEARCH Open Access Conditional ablation of p130Cas/BCAR1 adaptor protein impairs epidermal homeostasis by altering cell adhesion and differentiation Maria del Pilar Camacho Leal†, Andrea Costamagna†, Beatrice Tassone, Stefania Saoncella, Matilde Simoni, Dora Natalini, Aurora Dadone, Marianna Sciortino, Emilia Turco, Paola Defilippi, Enzo Calautti‡ and Sara Cabodi*‡ Abstract Background: p130 Crk-associated substrate (p130CAS; also known as BCAR1) is a scaffold protein that modulates many essential cellular processes such as cell adhesion, proliferation, survival, cell migration, and intracellular signaling. p130Cas has been shown to be highly expressed in a variety of human cancers of epithelial origin. However, few data are available regarding the role of p130Cas during normal epithelial development and homeostasis. Methods: To this end, we have generated a genetically modified mouse in which p130Cas protein was specifically ablated in the epidermal tissue. Results: By using this murine model, we show that p130Cas loss results in increased cell proliferation and reduction of cell adhesion to extracellular matrix. In addition, epidermal deletion of p130Cas protein leads to premature expression of “late” epidermal differentiation markers, altered membrane E-cadherin/catenin proteins localization and aberrant tyrosine phosphorylation of E-cadherin/catenin complexes. Interestingly, these alterations in adhesive properties in absence
    [Show full text]
  • Expression Profiling of KLF4
    Expression Profiling of KLF4 AJCR0000006 Supplemental Data Figure S1. Snapshot of enriched gene sets identified by GSEA in Klf4-null MEFs. Figure S2. Snapshot of enriched gene sets identified by GSEA in wild type MEFs. 98 Am J Cancer Res 2011;1(1):85-97 Table S1: Functional Annotation Clustering of Genes Up-Regulated in Klf4 -Null MEFs ILLUMINA_ID Gene Symbol Gene Name (Description) P -value Fold-Change Cell Cycle 8.00E-03 ILMN_1217331 Mcm6 MINICHROMOSOME MAINTENANCE DEFICIENT 6 40.36 ILMN_2723931 E2f6 E2F TRANSCRIPTION FACTOR 6 26.8 ILMN_2724570 Mapk12 MITOGEN-ACTIVATED PROTEIN KINASE 12 22.19 ILMN_1218470 Cdk2 CYCLIN-DEPENDENT KINASE 2 9.32 ILMN_1234909 Tipin TIMELESS INTERACTING PROTEIN 5.3 ILMN_1212692 Mapk13 SAPK/ERK/KINASE 4 4.96 ILMN_2666690 Cul7 CULLIN 7 2.23 ILMN_2681776 Mapk6 MITOGEN ACTIVATED PROTEIN KINASE 4 2.11 ILMN_2652909 Ddit3 DNA-DAMAGE INDUCIBLE TRANSCRIPT 3 2.07 ILMN_2742152 Gadd45a GROWTH ARREST AND DNA-DAMAGE-INDUCIBLE 45 ALPHA 1.92 ILMN_1212787 Pttg1 PITUITARY TUMOR-TRANSFORMING 1 1.8 ILMN_1216721 Cdk5 CYCLIN-DEPENDENT KINASE 5 1.78 ILMN_1227009 Gas2l1 GROWTH ARREST-SPECIFIC 2 LIKE 1 1.74 ILMN_2663009 Rassf5 RAS ASSOCIATION (RALGDS/AF-6) DOMAIN FAMILY 5 1.64 ILMN_1220454 Anapc13 ANAPHASE PROMOTING COMPLEX SUBUNIT 13 1.61 ILMN_1216213 Incenp INNER CENTROMERE PROTEIN 1.56 ILMN_1256301 Rcc2 REGULATOR OF CHROMOSOME CONDENSATION 2 1.53 Extracellular Matrix 5.80E-06 ILMN_2735184 Col18a1 PROCOLLAGEN, TYPE XVIII, ALPHA 1 51.5 ILMN_1223997 Crtap CARTILAGE ASSOCIATED PROTEIN 32.74 ILMN_2753809 Mmp3 MATRIX METALLOPEPTIDASE
    [Show full text]
  • Breast Cancer Antiestrogen Resistance-3 Expression Regulates Breast Cancer Cell Migration Through Promotion of P130cas Membrane Localization Andmembrane Ruffling
    Research Article Breast Cancer Antiestrogen Resistance-3 Expression Regulates Breast Cancer Cell Migration through Promotion of p130Cas Membrane Localization andMembrane Ruffling Randy S. Schrecengost,1 Rebecca B. Riggins,2 Keena S. Thomas,1 Michael S. Guerrero,1 and Amy H. Bouton1 1Department of Microbiology, University of Virginia Health System, Charlottesville, Virginia and 2Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia Abstract antiestrogen resistance-1 (BCAR1; also known as p130Cas; refs. 2, 3). Antiestrogens such as tamoxifen are widely used in the clinic A second protein, BCAR3 (the human homologue of the murine to treat estrogen receptor–positive breast tumors. Resistance protein AND-34), was identified in a genetic screen along with to tamoxifen can occur either de novo or develop over time in BCAR1 as a gene product whose overexpression conferred tamoxifen resistance in vitro (4). BCAR3 is a member of the novel a large proportion of these tumors. Additionally, resistance is S p associated with enhanced motility and invasiveness in vitro. rc homology 2 (SH2)–containing rotein (NSP) family that One molecule that has been implicated in tamoxifen resis- includes two other members, Chat/SHEP1 and NSP1. These tance, breast cancer antiestrogen resistance-3 (BCAR3), has proteins share a common domain structure consisting of an also been shown to regulate migration of fibroblasts. In this amino-terminal SH2 domain and a carboxyl-terminal domain with study, we investigated the role of BCAR3 in breast cancer cell sequence homology to the Cdc25-family of guanine nucleotide exchange factors (GEF). Several studies have shown that BCAR3 migration and invasion.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Paxillin: a Crossroad in Pathological Cell Migration Ana María López-Colomé*, Irene Lee-Rivera, Regina Benavides-Hidalgo and Edith López
    López-Colomé et al. Journal of Hematology & Oncology (2017) 10:50 DOI 10.1186/s13045-017-0418-y REVIEW Open Access Paxillin: a crossroad in pathological cell migration Ana María López-Colomé*, Irene Lee-Rivera, Regina Benavides-Hidalgo and Edith López Abstract Paxilllin is a multifunctional and multidomain focal adhesion adapter protein which serves an important scaffolding role at focal adhesions by recruiting structural and signaling molecules involved in cell movement and migration, when phosphorylated on specific Tyr and Ser residues. Upon integrin engagement with extracellular matrix, paxillin is phosphorylated at Tyr31, Tyr118, Ser188, and Ser190, activating numerous signaling cascades which promote cell migration, indicating that the regulation of adhesion dynamics is under the control of a complex display of signaling mechanisms. Among them, paxillin disassembly from focal adhesions induced by extracellular regulated kinase (ERK)- mediated phosphorylation of serines 106, 231, and 290 as well as the binding of the phosphatase PEST to paxillin have been shown to play a key role in cell migration. Paxillin also coordinates the spatiotemporal activation of signaling molecules, including Cdc42, Rac1, and RhoA GTPases, by recruiting GEFs, GAPs, and GITs to focal adhesions. As a major participant in the regulation of cell movement, paxillin plays distinct roles in specific tissues and developmental stages and is involved in immune response, epithelial morphogenesis, and embryonic development. Importantly, paxillin is also an essential player in pathological conditions including oxidative stress, inflammation, endothelial cell barrier dysfunction, and cancer development and metastasis. Keywords: Cancer, Focal adhesions, Cell migration, Signal transduction Background gene transcription, thus acting as a direct link from the Paxillin is a main component of focal adhesions (FAs) and plasma membrane and the cytoskeleton to the nucleus [5].
    [Show full text]
  • Identification of Transcriptional Mechanisms Downstream of Nf1 Gene Defeciency in Malignant Peripheral Nerve Sheath Tumors Daochun Sun Wayne State University
    Wayne State University DigitalCommons@WayneState Wayne State University Dissertations 1-1-2012 Identification of transcriptional mechanisms downstream of nf1 gene defeciency in malignant peripheral nerve sheath tumors Daochun Sun Wayne State University, Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations Recommended Citation Sun, Daochun, "Identification of transcriptional mechanisms downstream of nf1 gene defeciency in malignant peripheral nerve sheath tumors" (2012). Wayne State University Dissertations. Paper 558. This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. IDENTIFICATION OF TRANSCRIPTIONAL MECHANISMS DOWNSTREAM OF NF1 GENE DEFECIENCY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS by DAOCHUN SUN DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2012 MAJOR: MOLECULAR BIOLOGY AND GENETICS Approved by: _______________________________________ Advisor Date _______________________________________ _______________________________________ _______________________________________ © COPYRIGHT BY DAOCHUN SUN 2012 All Rights Reserved DEDICATION This work is dedicated to my parents and my wife Ze Zheng for their continuous support and understanding during the years of my education. I could not achieve my goal without them. ii ACKNOWLEDGMENTS I would like to express tremendous appreciation to my mentor, Dr. Michael Tainsky. His guidance and encouragement throughout this project made this dissertation come true. I would also like to thank my committee members, Dr. Raymond Mattingly and Dr. John Reiners Jr. for their sustained attention to this project during the monthly NF1 group meetings and committee meetings, Dr.
    [Show full text]
  • High BCAR1 Expression Is Associated with Early PSA Recurrence in ERG Negative Prostate Cancer Asmus Heumann1†, Nina Heinemann1†, Claudia Hube-Magg1, Dagmar S
    Heumann et al. BMC Cancer (2018) 18:37 DOI 10.1186/s12885-017-3956-3 RESEARCHARTICLE Open Access High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer Asmus Heumann1†, Nina Heinemann1†, Claudia Hube-Magg1, Dagmar S. Lang1, Katharina Grupp2, Martina Kluth1, Sarah Minner1, Christina Möller-Koop1,MarkusGraefen3, Hans Heinzer3, Maria Christina Tsourlakis1, Waldemar Wilczak1, Corinna Wittmer1,FrankJacobsen1,HartwigHuland3, Ronald Simon1* ,ThorstenSchlomm3,4, Guido Sauter1, Stefan Steurer1,PatrickLebok1 and Andrea Hinsch1 Abstract Background: Breast cancer anti-estrogen resistance 1 (BCAR1/p130cas) is a hub for diverse oncogenic signaling cascades and promotes tumor development and progression. Methods: To understand the effect of BCAR1 in prostate cancer, we analyzed its expression on more than 11,000 prostate cancer samples. BCAR1 expression levels were compared with clinical characteristics, PSA recurrence, molecular subtype defined by ERG status and 3p, 5q, 6q and PTEN deletion. Results: BCAR1 staining was barely detectable in normal prostate glands but seen in 77.6% of 9472 interpretable cancers, including strong expression in 38.5%, moderate in 23.2% and weak in 15.9% of cases. BCAR1 up regulation was associated with positive ERG status (p < 0.0001), high Gleason score (p < 0.0001), advanced pathological tumor stage (p = 0.0082), lower preoperative PSA level (p < 0.0001), increased cell proliferation (p < 0.0001), early PSA recurrence (p = 0.0008), and predicted prognosis independently from clinico-pathological parameters available at the time of the initial biopsy. However, subset analyses revealed that the prognostic impact of BCAR1 expression was limited to ERG-negative cancer. That BCAR1 up regulation was linked to almost all analyzed deletions (p < 0.0001 each for PTEN, 5q, 6q deletion) may suggest a functional link to genomic instability.
    [Show full text]
  • Association of Β1 Integrin with Focal Adhesion Kinase and Paxillin In
    The Journal of Neuroscience, May 15, 2000, 20(10):3776–3784 Association of ␤1 Integrin with Focal Adhesion Kinase and Paxillin in Differentiating Schwann Cells Li-Mei Chen, Debora Bailey, and Cristina Fernandez-Valle Department of Molecular Biology and Microbiology, University of Central Florida, Orlando, Florida 32816-2360, and Orlando Regional Healthcare System/Health Research Institute, Orlando, Florida 32806 Schwann cells (SCs) differentiate into a myelinating cell when grin, FAK, and paxillin molecules reside in the insoluble, simultaneously adhering to an axon destined for myelination F-actin-rich fraction of differentiating cocultures. Cytochalasin and basal lamina. We are interested in defining the signaling D, an actin depolymerizing agent, decreases tyrosine phos- pathway activated by basal lamina. Using SC/sensory neuron phorylation of FAK and paxillin and their association with ␤1 (N) cocultures, we identified ␤1 integrin and F-actin as compo- integrin and causes a dose-dependent increase in the abun- nents of a pathway leading to myelin gene expression and dance of insoluble FAK and paxillin complexes. Collectively, our myelination (Fernandez-Valle et al., 1994, 1997). Here, we show work indicates that ␤1 integrin, FAK, paxillin, and fyn kinase that focal adhesion kinase (FAK) and paxillin are constitutively form an actin-associated complex in SCs adhering to basal expressed by SCs contacting axons in the absence of basal lamina in the presence of axons. This complex may be impor- lamina. Tyrosine phosphorylation of FAK and paxillin increases tant for initiating the process of SC differentiation into a myeli- as SCs form basal lamina and differentiate. FAK and paxillin nating cell.
    [Show full text]
  • Grb7, a Critical Mediator of EGFR/Erbb Signaling, in Cancer Development and As a Potential Therapeutic Target
    cells Review Grb7, a Critical Mediator of EGFR/ErbB Signaling, in Cancer Development and as a Potential Therapeutic Target 1, 1,2, 1,3, Pei-Yu Chu y , Yu-Ling Tai y and Tang-Long Shen * 1 Department of Plant Pathology and Microbiology, National Taiwan University, Taipei 10617, Taiwan; [email protected] (P.-Y.C.); [email protected] (Y.-L.T.) 2 Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA 3 Center for Biotechnology, National Taiwan University, Taipei 10617, Taiwan * Correspondence: [email protected]; Tel.: +886-2-3366-4998 These authors contributed equally to this work. y Received: 30 March 2019; Accepted: 9 May 2019; Published: 10 May 2019 Abstract: The partner of activated epidermal growth factor receptor (EGFR), growth factor receptor bound protein-7 (Grb7), a functionally multidomain adaptor protein, has been demonstrated to be a pivotal regulator for varied physiological and pathological processes by interacting with phospho-tyrosine-related signaling molecules to affect the transmission through a number of signaling pathways. In particular, critical roles of Grb7 in erythroblastic leukemia viral oncogene homolog (ERBB) family-mediated cancer development and malignancy have been intensively evaluated. The overexpression of Grb7 or the coamplification/cooverexpression of Grb7 and members of the ERBB family play essential roles in advanced human cancers and are associated with decreased survival and recurrence of cancers, emphasizing Grb70s value as a prognostic marker and a therapeutic target. Peptide inhibitors of Grb7 are being tested in preclinical trials for their possible therapeutic effects. Here, we review the molecular, functional, and clinical aspects of Grb7 in ERBB family-mediated cancer development and malignancy with the aim to reveal alternative and effective therapeutic strategies.
    [Show full text]